New drug duo tested in fight against aggressive brain cancer
NCT ID NCT04656535
Summary
This early-phase study is testing the safety of a two-drug combination (domvanalimab and zimberelimab) for adults with glioblastoma that has returned after initial treatment. The main goal is to see if the drugs are safe for people with brain tumors and to learn how they affect the cancer and the body's immune response. Some participants will receive the drugs before planned surgery so researchers can study their effects directly on the tumor tissue.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
Yale University
New Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.